AP2M1 is a prognostic marker associated with cell cycle arrest and the tumor immune microenvironment in acute myeloid leukemia

Acute myeloid leukemia (AML) is a heterogeneous clonal disease of hematopoietic progenitor cells and the most common malignant myeloid disease in adults. Although significant progress has been made in treatment, the outlook remains bleak, and new therapeutic targets need to be sought. AP-2 complex subunit mu (AP2M1) is a core component of the clathrin-mediated endocytic machinery, AP2M1 plays a critical role in cancer progression. However, its function in acute myeloid leukemia (AML) progression remains unclear. Our study reveals that AP2M1 is highly expressed in AML and is associated with poor prognosis. Mechanistic studies suggest that this effect may result through cell cycle arrest and is associated with the tumor microenvironment, and our findings suggest that AP2M1 is a potential oncogene and prognostic marker for AML.

Authors

Institutions

Publication Details

Journal
Leukemia & lymphoma/Leukemia and lymphoma
Published
2025-05-19
DOI
https://doi.org/10.1080/10428194.2025.2504161
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

AP2M1 is a prognostic marker associated with cell cycle arrest and the tumor immune microenvironment in acute myeloid leukemia

Dayong Yao, Yue Su, Mengmeng Gu, Gang Hao et al.
Leukemia & lymphoma/Leukemia and lymphoma
Acute Myeloid Leukemia Research
article

AP2M1 is a prognostic marker associated with cell cycle arrest and the tumor immune microenvironment in acute myeloid leukemia

Dayong Yao, Yue Su, Mengmeng Gu, Gang Hao, Yanhong Zhao, Xinbo Zou, Zhiyu Liu, Wei Jia, Yang Li, Hui Liang, Ce Shi, Zhenkun Wang, Xin Zhang, Boqian Yu
article en

Abstract

Acute myeloid leukemia (AML) is a heterogeneous clonal disease of hematopoietic progenitor cells and the most common malignant myeloid disease in adults. Although significant progress has been made in treatment, the outlook remains bleak, and new therapeutic targets need to be sought. AP-2 complex subunit mu (AP2M1) is a core component of the clathrin-mediated endocytic machinery, AP2M1 plays a critical role in cancer progression. However, its function in acute myeloid leukemia (AML) progression remains unclear. Our study reveals that AP2M1 is highly expressed in AML and is associated with poor prognosis. Mechanistic studies suggest that this effect may result through cell cycle arrest and is associated with the tumor microenvironment, and our findings suggest that AP2M1 is a potential oncogene and prognostic marker for AML.

Leukemia & lymphoma/Leukemia and lymphomaVol. 66(9)
Harbin Medical University (CN), Third Affiliated Hospital of Harbin Medical University (CN), First Affiliated Hospital of Harbin Medical University (CN)
Good health and well-being
Openalex Percentile: Top 86%
Acute Myeloid Leukemia Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.